Xiaofeng Zeng

New Capabilities

Professor at Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences

Roughly a third of rheumatoid arthritis patients don't get adequate relief from biologic drugs, the standard treatment after methotrexate. Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib kept 91.8% of those patients at an ACR20 response through 76 weeks.

Updated 2 hours ago